Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Estrella Immunopharma Inc. (ESLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ESLA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16
1 Year Target Price $16
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.89% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 31.12M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 1 | Beta 0.34 | 52 Weeks Range 0.63 - 1.78 | Updated Date 08/15/2025 |
52 Weeks Range 0.63 - 1.78 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.11 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -100.93% | Return on Equity (TTM) -268.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9278877 | Price to Sales(TTM) - |
Enterprise Value 9278877 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.07 | Shares Outstanding 36165600 | Shares Floating 10336481 |
Shares Outstanding 36165600 | Shares Floating 10336481 | ||
Percent Insiders 70.36 | Percent Institutions 1.7 |
Upturn AI SWOT
Estrella Immunopharma Inc.
Company Overview
History and Background
As of November 24, 2024, there is no publicly traded US stock named 'Estrella Immunopharma Inc.'. Therefore, it is impossible to provide accurate information about its history, milestones, or evolution.
Core Business Areas
Leadership and Structure
As 'Estrella Immunopharma Inc.' is not a known entity, I can't define its leadership team and structure.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Without a valid company, I cannot summarize the relevant industry.
Positioning
Since 'Estrella Immunopharma Inc.' is not a known entity, I can't determine its positioning within the industry.
Total Addressable Market (TAM)
Since 'Estrella Immunopharma Inc.' is not a known entity, I can't determine the TAM.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Without a valid company, I cannot evaluate the competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Since 'Estrella Immunopharma Inc.' is not a known entity, I can't discuss its growth trends.
Future Projections: Since 'Estrella Immunopharma Inc.' is not a known entity, I can't provide future projections.
Recent Initiatives: Since 'Estrella Immunopharma Inc.' is not a known entity, I can't highlight recent initiatives.
Summary
Based on the current information, Estrella Immunopharma Inc. does not appear to be a publicly traded company, rendering it impossible to accurately asses its performance and operations. Additional information or clarification of the correct company name or stock symbol is needed to proceed. The lack of available data prevents a comprehensive assessment of the company's strengths, weaknesses, opportunities, and threats. Without verifiable information, no valid conclusions can be drawn about the company's potential or risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available financial databases and search engines were queried. No relevant data was found.
Disclaimers:
The information provided is based on the lack of publicly available data for 'Estrella Immunopharma Inc.'. This analysis is based on the absence of evidence and should not be interpreted as a reflection of any real-world company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Estrella Immunopharma Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2021-09-14 | CEO, President & Director Dr. Cheng Liu Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.estrellabio.com |
Full time employees - | Website https://www.estrellabio.com | ||
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.